Interaction between PPARA genotype and beta-blocker treatment influences clinical outcomes following acute coronary syndromes.

ABSTRACT:

Aims

beta-blockers (BB) are strongly recommended after an acute coronary syndrome (ACS), although all patients may not benefit. Causes for variable patient responses to BB are unknown. Given that myocardial ischemia and BB influence metabolic processes regulated by peroxisome proliferator-activated receptor alpha (PPARalpha), we hypothesized that interactions between polymorphisms of the PPARalpha gene (PPARA) and BB treatment would influence clinical outcome following ACS.

Patients & methods

Patients were prospectively enrolled into an ACS registry. A total of 735 ACS patients were genotyped. Mortality and cardiac rehospitalization through 1 year were analyzed in relation to PPARA genotype and BB prescription (597 BB; 138 no BB) at discharge.

Results

Significantly di

SUBMITTER: Cresci S 

PROVIDER: S-EPMC2586954 | biostudies-literature | 2008 Oct

REPOSITORIES: biostudies-literature